Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors Lewis, K. D., Perris, K., Sekulic, A., Stratigos, A., Duecker, P., Eroglu, Z., Chang, A. S., Migden, M. R., Yoo, S. Y., Mohan, K., Coates, E., Okoye, E., Baurain, J. F., Bechter, O., Hauschild, A., Butler, M. O., Hernandez-Aya, L., Licitra, L., Neves, R. I., Ruiz, E. S., Seebach, F., Lowy, I., Goncalves, P., Fury, M. G. WILEY. 2022: 105-106

View details for Web of Science ID 000851869200181